07:00 , Jun 25, 2015 |  BC Innovations  |  Product R&D

Cellectis' UCART-ography

A year after Pfizer Inc. threw its weight behind Cellectis S.A.'s chimeric antigen receptor (CAR) T cell platform, the biotech has signed a three-year partnership with Weill Cornell Medical College to test whether its system...
07:00 , Jun 11, 2015 |  BC Innovations  |  Product R&D

All four one

Amphivena Therapeutics Inc. licensed Affimed N.V.'s tetravalent antibody-mimetic technology two years ago to create blood cancer therapeutics that would be simpler to use and safer than CAR T cell therapies. Now, the start-up has presented...